Abbott ’s reported third-quarter 2020 global sales of $8.9bn beat Wall Street estimates by $314m, driven by its strong position in COVID-19 tests, which reached $881m in sales this quarter, and a strong return in medtech sales, particularly in diabetes care.
After a tough second quarter, the company’s third-quarter sales rose 9.6% from $8.07bn in the third quarter a year ago,...







